COMMUNIQUÉS West-GlobeNewswire

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22/10/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
22/10/2025
MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory [...]
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
22/10/2025
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously [...]
Ipsen annonce son intention d’acquérir ImCheck Therapeutics et étend son leadership en oncologie avec un portefeuille enrichi de produits en R&D
22/10/2025
Acquisition axée sur le programme clinique phare ICT01 dans le domaine de la leucémie myéloïde aiguë, dont les données issues de l'essai EVICTION de phase I/II en cours ont montré une réponse thérapeutique élevée. ICT01 [...]
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
22/10/2025
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of [...]
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine
22/10/2025
L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine L’efdoralprine alfa a démontré sa [...]
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
22/10/2025
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care [...]
Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2025 et revoit à la hausse ses prévisions pour l'exercice en cours
22/10/2025
Croissance du chiffre d’affaires du Groupe de 12,1 % à taux de change constant 1 au cours des neuf premiers mois de l’année 2025, ou 9,6 % en données publiées, portée par les trois aires thérapeutiques et incluant les [...]
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
22/10/2025
Year-to-date total sales growth of 12.1% at CER 1 , or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 [...]
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
22/10/2025
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; [...]
SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie
22/10/2025
Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie Spineway, spécialiste des implants innovants pour le traitement des pathologies [...]
Aveanna Announces Pricing of Secondary Offering of Common Stock
22/10/2025
ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, [...]
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
22/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and [...]
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
22/10/2025
SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite [...]
Fairhaven Health Highlights Science-Driven Solutions for Women During Menopause Awareness Month
21/10/2025
MIDDLETOWN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- October marks Menopause Awareness Month, a time to focus on the physical and emotional changes that affect more than 1 million American women each year. Fairhaven [...]
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
21/10/2025
BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
21/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and [...]
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
21/10/2025
Highlighting Regulatory and Clinical Leadership in Regenerative Exosome Therapies TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/10/2025
CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]

Pages